Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819021 · ClinicalTrials.gov registry record
Open Label Optimization Study
A clinical trial of Major Depressive Disorder, sponsored by Magnus Medical.
- Active
- Registry status
- 1,000
- Enrollment target
- 7
- Study locations
NCT05819021: Active study of Major Depressive Disorder, sponsored by Magnus Medical.
NCT05819021 is a study of Major Depressive Disorder that is active but no longer recruiting, run by Magnus Medical. The registered enrollment target is 1,000 participants, above the 373-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (168% higher). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05819021, a study of Major Depressive Disorder, is active but no longer recruiting, sponsored by Magnus Medical.
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment Participants will receive 10 treatments per day for 5 days (M-F) of SAINT®
Primary Outcome
Clinical Global Impression-Improvement (CGI-I) score is based on a scale from zero (0) - Not Assessed to seven (7) Very Much Worse with lower scores showing improvement and higher scores showing little or no improvement.
Conditions Studied
Interventions
- DEVICE SAINT® Neuromodulation System (NMS)
Study Locations (7)
California
- BrainHealth Solutions - Costa Mesa
- LA TMS - Los Angeles
- Integral TMS - Sunnyvale
- Acacia Research Center - Sunnyvale
Massachusetts
- Boston Precision Neurotherapeutics - Natick
New York
- Fermata - Brooklyn
Washington
- Seattle Neuropsychiatric Treatment Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-04-06 |
| Est. Completion | 2027-04-15 |
What the registry record for NCT05819021 still lists
NCT05819021 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 373-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (168% higher).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which SAINT® Neuromodulation System (NMS) is the first listed.
NCT05819021 lists 7 locations in 4 states (California, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT05819021 about?
NCT05819021 is a clinical study titled "Open Label Optimization Study". The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment Participants will receive 10 treatments ...
What is the current status of trial NCT05819021?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2023-04-06. Estimated completion is 2027-04-15.
What conditions does trial NCT05819021 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05819021?
The interventions under investigation include: SAINT® Neuromodulation System (NMS) (DEVICE).
Who is sponsoring clinical trial NCT05819021?
This trial is sponsored by Magnus Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05819021 being conducted?
This trial has 7 study locations across California, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05819021's enrollment target sits among peer trials
1,000 7th of 282 higher than 274 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Taking Action for College Students
RECRUITING · NA
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI